Biliary Atresia

Etiology

Biliary atresia is a complex, progressive cholangiopathy of infancy with an incompletely defined etiology. Current evidence supports the concept that this condition represents a final common phenotype resulting from multiple, potentially convergent pathogenic pathways, including genetic susceptibility, disordered embryological development, immune-mediated bile duct injury, and acquired inflammatory or infectious insults.[4][5] Many experts propose a "2-hit" model, wherein a postnatal inflammatory or infectious insult follows a prenatal developmental vulnerability.

Genetic and Embryologic Factors

Syndromic associations occur in 3% to 20% of cases, and the geographic variability in incidence suggests a genetic contribution, although familial aggregation is rare. Embryologically, the nonsyndromic form may result from defective ductal plate remodeling at the hepatic hilum.[6] Molecular studies indicate persistence of immature cholangiocyte phenotypes. Recent evidence points to biliary atresia as a potential ciliopathy, where defects in cholangiocyte ciliary structure impair ductal development and bile flow.[7]

Acquired Inflammatory and Infectious Triggers

Postnatal insults are suggested by epidemiologic observations such as seasonal clustering of cases and the evolution from initially pigmented to acholic stools in affected infants. Viral infections, including rotavirus and reovirus type 3, have been implicated in animal models, while human studies remain inconclusive. Cytomegalovirus (CMV) infection defines a distinct clinical subset marked by higher bilirubin and transaminase levels, pronounced histologic inflammation, and generally poorer outcomes.[8] Results from recent retrospective studies in 2025 suggest that CMV status may modulate disease severity and biochemical profile, rather than directly influencing postoperative cholangitis.[9]

Immune-Mediated Mechanisms

Dysregulated immune responses are central to the progression of bile duct injury. Histopathology demonstrates increased expression of intercellular adhesion molecule-1, recruitment of CD4+, CD8+, natural killer lymphocytes, and persistent activation of innate and adaptive immune pathways.[10] Recent immunophenotyping studies in children with portal hypertension secondary to biliary atresia confirm that chronic immune activation contributes to fibrosis and portal hypertensive complications.

Classification

Biliary atresia is a heterogeneous condition, classified both clinically and morphologically.[11]

Clinical/Phenotypic Classification

• Biliary atresia splenic malformation (BASM) syndrome (~10%)
  • This is characterized by laterality defects (polysplenia, situs inversus), vascular anomalies (preduodenal portal vein, interrupted inferior vena cava), cardiac malformations, and intestinal malrotation, reflecting very early embryologic disruption.[12]
• Cardiac-associated biliary atresia 
  • A distinct prognostic subgroup defined by the presence of significant structural cardiac anomalies (eg, septal defects, tetralogy of Fallot). These cases may or may not include other BASM features and are associated with poorer outcomes.[13]
• Other syndromic associations
  • There are rare links to cat-eye syndrome and Kabuki syndrome.
• Cystic biliary atresia (~10%)
  • This type exhibits cystic dilatation at the porta hepatis; it is typically diagnosed early and is associated with favorable outcomes post-Kasai.[14]
• CMV immunoglobulin M (IgM)-positive biliary atresia (~10%)
  • A distinct inflammatory subset with higher bilirubin and aspartate aminotransferase levels, prominent inflammatory infiltrates on histology, and poorer prognosis.[15]
• Isolated biliary atresia (~70%)
  • The most common form, lacking congenital anomalies, has a multifactorial etiology, with contributions from developmental susceptibility and postnatal inflammatory injury.

Morphological Classification (Japanese Association of Pediatric Surgeons)

• Type I: Obliteration of the common bile duct
• Type IIa: Obliteration of the common hepatic duct
• Type IIb: Obliteration of the common bile duct, hepatic duct, and cystic duct with a patent gallbladder
• Type III: Obliteration at the porta hepatis with no anastomosable ducts; the most common and surgically challenging (>90% of cases)

Epidemiology

Biliary atresia exhibits marked geographic and ethnic variation in incidence, underscoring its complex, multifactorial etiology. Globally, it is a rare disorder, with the highest reported rates observed in East Asia. In Taiwan and Japan, incidence estimates range from approximately 1 in 5000 to 1 in 10,000 live births.[16][17] Conversely, populations in Western nations, such as England and Wales, demonstrate lower incidence rates, typically between 1 in 15,000 and 1 in 20,000 live births.[18] These disparities likely reflect underlying genetic susceptibility, regional environmental factors, and potential differences in diagnostic ascertainment.

Further supporting an environmental component, results from several studies have identified seasonal clustering of cases, with peaks often reported in winter months.[19] Although this pattern is not universal, it lends credence to the hypothesis that perinatal infectious or other environmental triggers may contribute to disease pathogenesis in genetically susceptible infants. A consistent, slight female predominance has been noted across diverse cohorts, though the pathophysiological basis for this gender disparity remains unexplained.

Epidemiologic patterns also extend to the distribution of disease subtypes. BASM syndrome accounts for roughly 10% of cases in European series but is reported less frequently in Asian populations. In contrast, CMV IgM-positive biliary atresia is more commonly reported in East Asian cohorts, particularly in China, and is associated with more pronounced biochemical inflammation and poorer clinical outcomes. Collectively, these epidemiological observations reinforce that biliary atresia is a heterogeneous condition influenced by an interplay of genetic, environmental, and regional factors.

Histopathology

Histological examination of liver tissue in biliary atresia shows a spectrum of changes reflecting the stage and severity of disease at presentation. Common findings include portal tract expansion with variable degrees of fibrosis, marked bile duct proliferation, bile duct plugging, canalicular and hepatocellular cholestasis, and mixed inflammatory cell infiltration. As the disease progresses, these changes may evolve into bridging fibrosis and established biliary cirrhosis.

Among these features, bile duct proliferation is considered one of the most characteristic histopathologic findings in biliary atresia and is a highly sensitive marker for the disease in the appropriate clinical context.[20] When combined with portal fibrosis and cholestasis, this feature helps distinguish biliary atresia from other causes of neonatal cholestasis. However, histologic findings must be interpreted in the context of clinical, laboratory, and imaging data, as overlap with other cholestatic disorders can occur, particularly in early disease.

History and Physical

Infants with biliary atresia typically present in the neonatal period with persistent jaundice beyond the second week of life, acholic or pale stools, dark urine, and hepatomegaly.[21] Jaundice persisting for more than 14 days should not be considered physiological and warrants prompt evaluation for cholestatic liver disease. Early clinical presentation may be subtle, and several studies emphasize that a proportion of infants initially pass pigmented stools that progressively become acholic as bile flow deteriorates, contributing to delayed diagnosis.

Recent cohort data reinforce that delayed recognition of stool color change remains a major factor influencing outcomes after Kasai portoenterostomy. Nugraheni et al demonstrated that earlier age at diagnosis and intervention was significantly associated with improved 5-year native liver survival, highlighting the importance of early clinical suspicion during routine neonatal follow-up. This supports the clinical emphasis on early stool surveillance and timely referral.[22]

As the disease progresses, signs of chronic liver injury and portal hypertension become evident. These include firm hepatomegaly, splenomegaly, ascites, failure to thrive, and, in advanced cases, features of hepatic synthetic dysfunction. Di Dato et al described distinct immunological alterations in children with portal hypertension, including systemic immune activation and inflammatory profiles that correlate with disease severity. These findings provide a mechanistic basis for the progressive clinical deterioration observed on physical examination in advanced biliary atresia.[23]

Infectious and syndromic associations may also influence presentation. Study results from East Asia show a higher prevalence of CMV IgM positivity in biliary atresia, which has been associated with more aggressive inflammatory cholangitis and worse postoperative outcomes. Additionally, rare overlap with syndromic conditions such as cat-eye syndrome, CABA, and Alagille Syndrome has been reported, underscoring the need for careful evaluation of cardiac, vertebral, and facial features during physical examination when atypical findings are present.[24][25] Overall, careful assessment of jaundice duration, stool color evolution, growth parameters, hepatosplenomegaly, and early signs of portal hypertension remains central to diagnosis. Recent evidence strongly supports the conclusion that early recognition during history and physical examination directly affects long-term survival outcomes.

Evaluation

No single investigation can diagnose biliary atresia with high specificity. Diagnosis, therefore, relies on a structured, sequential approach that integrates clinical assessment, laboratory biomarkers, imaging, and histopathology. Timely progression through this pathway is essential, as diagnostic delay significantly reduces the success of Kasai portoenterostomy and long-term survival of the native liver.

Laboratory Studies

Laboratory evaluation reveals conjugated hyperbilirubinemia with elevation of both total and direct bilirubin. Serum aminotransferases are typically mildly to moderately elevated but nonspecific. Alkaline phosphatase is often elevated in infancy due to bone growth, which limits its diagnostic utility; liver-specific enzymes, such as 5′-nucleotidase, offer greater specificity. Gamma-glutamyl transpeptidase (GGTP), localized to the cholangiocyte canalicular membrane, is commonly elevated in obstructive cholestasis and helps differentiate biliary atresia from low-GGTP disorders such as progressive familial intrahepatic cholestasis. However, its diagnostic performance remains modest, with sensitivity and specificity of approximately 50% to 60%, supporting its role as a supportive rather than definitive marker.[26][27]

A highly promising biomarker is serum matrix metalloproteinase-7 (MMP-7), which reflects cholangiocyte injury and ductal remodeling.[28] In multiple cohorts, MMP-7 has demonstrated superior diagnostic accuracy compared to GGTP, strongly discriminating biliary atresia from other causes of neonatal cholestasis. While not yet universally available, MMP-7 is increasingly incorporated into contemporary diagnostic algorithms and multivariable prediction models.

Imaging Studies

Ultrasonography

Abdominal ultrasonography is the first-line imaging modality due to its wide availability and noninvasive nature. This modality assesses liver parenchyma, portal venous anatomy, and splenic size while excluding structural anomalies such as choledochal cysts. Typical findings include an absent or hypoplastic gallbladder and failure of postprandial gallbladder contraction.  

The triangular cord sign, an echogenic fibrotic remnant at the porta hepatis, has high specificity but variable sensitivity and notable interobserver variability.[29][30] Antenatal ultrasonography may detect gallbladder abnormalities in syndromic forms, facilitating early postnatal referral. The overall diagnostic accuracy of ultrasound alone is approximately 70% to 80%.

Hepatobiliary scintigraphy

Hepatobiliary scintigraphy using technetium-labeled iminodiacetic acid derivatives evaluates biliary excretion. Intestinal tracer excretion reliably excludes biliary atresia; however, absence of excretion is not diagnostic, as severe hepatocellular dysfunction (eg, in neonatal hepatitis) can yield similar findings, particularly with marked hyperbilirubinemia. False-positive and false-negative rates approach 10%.[31]

Endoscopic retrograde cholangiopancreatography 

This test is not routinely performed in neonates due to technical constraints and limited expertise. In specialized centers, it can directly delineate biliary anatomy and may prevent unnecessary surgical exploration. Emerging techniques, including artificial intelligence-assisted image interpretation, may have an adjunctive role in equivocal cases.

MRI and MR cholangiopancreatography 

These imaging modalities offer detailed, noninvasive visualization of the biliary tree and hepatic parenchyma. Routine use is limited by cost, need for sedation, and reduced spatial resolution in neonates; thus, it is generally reserved for complex or atypical presentations.

Duodenal Intubation

Duodenal intubation with bile aspiration can exclude biliary atresia but is invasive, technically challenging, and unreliable. This technique has largely been abandoned in contemporary diagnostic pathways.

Histopathological Evaluation

Percutaneous liver biopsy remains 1 of the most accurate diagnostic tools. Characteristic features include bile duct proliferation, canalicular bile plugging, portal tract edema and fibrosis, portal inflammatory infiltrates, and extramedullary hematopoiesis. Bile duct proliferation is the most sensitive and specific histological hallmark. Results from recent immunopathologic studies demonstrate marked activation of innate and adaptive immune pathways within portal tracts, underscoring the immune-mediated nature of bile duct injury. When interpreted by experienced pediatric pathologists, liver biopsy provides a high diagnostic yield and is pivotal for timely surgical decision-making.

Integrated Diagnostic Models and Emerging Approaches 

Recent advances emphasize multivariable diagnostic models over reliance on single tests. Predictive models incorporating clinical features (age, stool color, hepatomegaly) and biomarkers (total bilirubin, GGTP, MMP-7) have demonstrated substantially improved accuracy. Several contemporary studies report that models including MMP-7 achieve high sensitivity and specificity, facilitating earlier differentiation and expedited surgical referral.  

Screening algorithms that combine serum biomarkers with ultrasonographic parameters, such as gallbladder morphology and the triangular cord sign, show particular promise in high-volume centers, reducing diagnostic uncertainty and potentially decreasing the need for invasive investigations.  

Artificial intelligence (AI) and machine learning tools are emerging adjuncts. Early validation studies demonstrate that AI-assisted interpretation of ultrasound, endoscopic retrograde cholangiopancreatography, and integrated clinical data can improve diagnostic consistency and reduce interobserver variability. While not yet standard of care, these tools represent a future framework for population-level screening and risk stratification.[32]

From an immunologic perspective, inflammatory and immune activation markers are under investigation. Distinct immune profiles characterized by persistent innate and adaptive activation are observed, reinforcing biliary atresia as an immune-mediated fibroinflammatory process and informing future biomarker-driven models.Together, these integrated diagnostic strategies reflect a shift from isolated testing toward structured, evidence-based pathways. Their adoption could shorten diagnostic latency, optimize the timing of Kasai portoenterostomy, and ultimately improve native liver survival in children with biliary atresia.

Treatment / Management

Despite advances in noninvasive diagnostics, surgical exploration remains the only definitive method for both confirming the diagnosis of biliary atresia and initiating curative-intent treatment. Once biliary atresia is strongly suspected, prompt operative evaluation is essential, as surgical timing is the single most important modifiable determinant of outcome.

Perioperative Cholangiography

Intraoperative cholangiography is the diagnostic gold standard. Failure of contrast passage into the intrahepatic and extrahepatic biliary system confirms biliary atresia and distinguishes it from other causes of neonatal cholestasis. When biliary patency is demonstrated, unnecessary portoenterostomy can be avoided. The routine use of perioperative cholangiography ensures diagnostic certainty and allows immediate transition to definitive surgical correction during the same operation.[33]

Kasai Portoenterostomy

The standard surgical treatment is the Roux-en-Y hepatic portoenterostomy, commonly referred to as the Kasai procedure. This operation involves complete excision of the fibrotic extrahepatic biliary remnant and meticulous transection of the fibrous portal plate, with dissection extending to the level of the portal vein bifurcation. A Roux-en-Y jejunal limb is then anastomosed directly to the exposed porta hepatis, allowing bile drainage from residual microscopic bile ductules.

Early performance of the Kasai procedure, ideally before 60 days of life, is strongly associated with improved bile flow, lower rates of cholangitis, and enhanced survival of the native liver. Data presented at recent international surgical meetings, including the 58th Annual Meeting of the Pacific Association of Pediatric Surgeons, continue to reinforce that age at surgery and quality of portal plate dissection are critical determinants of outcomes. Minimally invasive approaches to Kasai portoenterostomy have been explored. However, recent real-world cohort data comparing open and laparoscopic Kasai procedures in patients ultimately requiring liver transplantation demonstrate no clear long-term advantage of laparoscopy and suggest potential concerns regarding adequacy of portal plate dissection. Consequently, open Kasai portoenterostomy remains the preferred approach in most high-volume centers.[34](B2)

Alternative Surgical Techniques

In rare cases where the gallbladder and common bile duct are patent, portocholecystostomy has been described. However, this technique is limited by reduced anastomotic flexibility and a higher risk of recurrent biliary obstruction, often necessitating revision. Long-term outcomes are inferior to those of standard portoenterostomy, despite a slightly lower incidence of postoperative cholangitis. Hepaticojejunostomy has been attempted in select patients with type I biliary atresia, but outcomes are consistently inferior to the Kasai procedure, and it is not routinely recommended.

Postoperative Adjunctive Medical Therapy

Adjunctive pharmacologic therapy is commonly used following Kasai portoenterostomy to promote bile flow and reduce inflammation. Ursodeoxycholic acid, a hydrophilic bile acid, enhances bile secretion and is widely prescribed postoperatively. Corticosteroids have been extensively studied for their potential to reduce inflammatory injury and accelerate bile clearance.

Early randomized trials demonstrated increased rates of jaundice clearance with low-dose prednisolone but no improvement in transplant-free survival. The START trial further showed that high-dose steroid therapy did not improve bile drainage at 6 months and was associated with earlier and more frequent adverse effects. Current evidence does not support routine high-dose steroid use, and practice patterns vary across centers.[35] Antibiotic prophylaxis is often employed to reduce the risk of ascending cholangitis, particularly in the early postoperative period. Emerging data also suggest that CMV-associated biliary atresia may have a higher burden of postoperative cholangitis, underscoring the importance of tailored postoperative surveillance in this subgroup.[36][37](A1)

Liver Transplantation

Liver transplantation is the definitive therapy for children with failed Kasai portoenterostomy or advanced biliary cirrhosis. Indications include persistent cholestasis, recurrent cholangitis, portal hypertension, growth failure, and hepatic synthetic dysfunction. Advances in pediatric transplantation have led to excellent long-term survival, and transplantation is now viewed as a complementary rather than a competing strategy to portoenterostomy. The modern management paradigm emphasizes a sequential approach in which timely Kasai portoenterostomy is performed to maximize native liver survival, with early referral for transplantation evaluation when disease progression becomes evident. This integrated strategy has transformed biliary atresia from a universally fatal condition into a chronic disease with favorable long-term outcomes when managed in specialized centers.

Differential Diagnosis

Differentiating biliary atresia from other causes of neonatal cholestasis is essential, as several conditions share overlapping clinical and biochemical features but require fundamentally different management strategies. Unlike biliary atresia, many alternative diagnoses are managed medically or follow a nonprogressive course, making early distinction critical to avoid unnecessary surgery or delayed intervention. Key considerations include genetic, infectious, metabolic, and structural hepatobiliary disorders, including the following:

• Alagille syndrome
• Alpha-1 antitrypsin deficiency
• TORCH (toxoplasmosis, others, rubella, CMV, herpes simplex virus)
• Caroli disease
• Choledochal cyst
• Idiopathic neonatal hepatitis
• Lipid metabolism disorders
• Total parenteral nutrition-associated cholestasis

Careful integration of clinical presentation, laboratory markers such as GGTP and MMP-7, imaging findings, and histopathology is often required to reliably distinguish biliary atresia from these entities, particularly in early infancy when features may be subtle.

Prognosis

Age at Initial Operation

Progression of hepatic fibrosis in biliary atresia is time-dependent, making early surgical intervention a critical determinant of outcome. However, the relationship between age at portoenterostomy and prognosis is not strictly linear. Earlier cohort analyses demonstrated that, in isolated biliary atresia, outcomes could not be reliably predicted by age alone up to approximately 90 days of life, suggesting that disease biology and postoperative bile flow also play major roles.

More recent data refine this understanding. Contemporary survival analyses, including 5-year outcome studies, confirm that surgery performed before 60 days of age is associated with higher rates of jaundice clearance and improved native liver survival, while outcomes decline progressively beyond 90 days. Nevertheless, age should not be used as an absolute exclusion criterion, as meaningful bile drainage and prolonged native liver survival have been documented even in later presenters when effective bile flow is achieved.[38][39][40]

Syndromic Biliary Atresia

Infants with syndromic biliary atresia, particularly those with biliary atresia splenic malformation syndrome, consistently demonstrate poorer outcomes following Kasai portoenterostomy. These patients often have advanced hepatic fibrosis at presentation and associated cardiovascular, vascular, and intestinal anomalies that complicate perioperative management. Multiple studies report lower rates of bile drainage, increased need for early liver transplantation, and higher mortality compared with isolated biliary atresia. Recent case-based reports further highlight diagnostic overlap between biliary atresia and other genetic syndromes, emphasizing the importance of careful phenotypic and genetic evaluation in atypical cases.

CMV-Associated Biliary Atresia

CMV IgM-positive biliary atresia represents a distinct inflammatory phenotype with the poorest overall prognosis. These infants present with higher bilirubin levels, elevated transaminases, and more severe portal inflammation on histology. Recent studies link CMV positivity to increased rates of postoperative cholangitis, accelerated fibrosis, and reduced transplant-free survival. Five-year survival analyses confirm CMV IgM positivity as an independent adverse prognostic factor following portoenterostomy, underscoring the need for intensified surveillance and early transplant planning in this subgroup.

Postoperative Bile Flow and Jaundice Clearance

Achievement of effective bile drainage after portoenterostomy is the strongest predictor of long-term native liver survival. Infants who clear jaundice within 3 to 6 months after surgery demonstrate significantly improved outcomes, whereas persistent cholestasis predicts early progression to cirrhosis and transplantation. Long-term follow-up studies show that patients surviving beyond 2 decades with their native liver typically exhibit normal or only mildly abnormal liver biochemistry in the early postoperative period. Serum markers measured after surgery have prognostic value. Lower bilirubin levels at 3 months and reduced gamma-glutamyl transpeptidase and aminotransferase levels at 1 year correlate with sustained hepatic function. Recent survival models further incorporate early postoperative trends in bilirubin and transaminases as key predictors of 5-year outcomes.

Histologic and Microscopic Ductal Factors

The size and density of residual microscopic bile ductules at the porta hepatis have been proposed as prognostic indicators, with larger and more numerous ductal structures theoretically facilitating bile drainage. Some histopathologic studies support this association, while others fail to demonstrate consistent predictive value, likely reflecting variability in sampling, surgical technique, and disease heterogeneity. Current consensus suggests that while ductal morphology may contribute to outcome, it is secondary to the quality of portal plate dissection and the postoperative inflammatory response.

Emerging Prognostic Factors

Recent studies have highlighted additional determinants of outcomes after portoenterostomy. Advanced liver fibrosis at diagnosis, elevated serum MMP-7 levels, recurrent postoperative cholangitis, and early development of portal hypertension are increasingly recognized as markers of poor prognosis. Immunologic profiling demonstrates persistent innate and adaptive immune activation in patients with unfavorable outcomes, linking immune-mediated injury to progressive fibrosis despite bile drainage.

Extrahepatic complications such as cirrhotic cardiomyopathy have also been described in children with longstanding biliary atresia, reflecting the systemic impact of chronic liver disease and influencing long-term morbidity. Collectively, these findings reinforce that the post-portoenterostomy outcome is multifactorial. While early surgery remains essential, disease phenotype, viral associations, immune activity, postoperative bile flow, and early biochemical response ultimately determine long-term survival of the native liver and the timing of liver transplantation.[24][41]

Complications

Despite successful portoenterostomy, biliary atresia remains a progressive fibroinflammatory disease. Postoperative complications are common and significantly influence long-term native liver survival, quality of life, and the timing of liver transplantation. Major complications include cholangitis, portal hypertension and its sequelae, ascites, intrahepatic biliary cyst formation, hepatopulmonary syndrome, and, rarely, malignancy:

Cholangitis

Ascending cholangitis is the most frequent and clinically significant complication, occurring in 40% to 60% of patients, with incidence peaking within the first postoperative year. The Roux-en-Y loop permits bacterial colonization, with additional risk factors including impaired bile flow and immune dysregulation. A 2025 meta-analysis of 57 studies has elucidated specific modifiable risk and protective factors. Key patient- and disease-related risk factors include age at surgery exceeding 60 days, high risk of malnutrition, low vitamin D Receptor expression, the presence of intrahepatic biliary cysts ("bile lakes"), and persistent postoperative jaundice.[42]

The CMV-associated phenotype is also associated with increased incidence and severity. Conversely, several interventions have been identified as protective factors, including the construction of an anti-reflux valve during surgery and postoperative administration of steroids (both standard- and high-dose regimens) or probiotics. Notably, evidence for routine prophylactic antibiotics remains inconsistent, with systematic reviews reporting conflicting efficacy findings.[43]

Clinically, cholangitis presents with fever, worsening jaundice, acholic stools, and elevated liver enzymes. Management requires prompt hospitalization with broad-spectrum intravenous antibiotics. Recurrent or refractory episodes accelerate fibrosis, reduce native liver survival, and increase the hazard for progression to liver failure.

Portal hypertension and sequelae

Portal hypertension develops in most children due to progressive fibrosis, with severity correlating with age at surgery, degree of preoperative fibrosis, and recurrent cholangitis. Distinct immune activation profiles are observed in children with portal hypertension, supporting the concept of ongoing immune-mediated injury. The major sequelae of this define long-term morbidity:

• Variceal bleeding
  • Esophageal and gastric varices develop in approximately 60% of patients with portal hypertension within 2 to 3 years, with nearly one-third experiencing a bleed. Management involves routine endoscopic surveillance, with acute bleeding requiring urgent band ligation or sclerotherapy.
• Ascites
  • Managed with sodium restriction and diuretics (spironolactone as first-line therapy). Refractory ascites signals advanced disease and often precedes transplant referral.

Intrahepatic biliary cysts

These "bile lakes" within the cirrhotic liver serve as a persistent nidus for recurrent cholangitis. Prolonged or repeated antibiotic therapy is often required, with failure to control infection or associated progressive hepatic dysfunction constituting a strong indication for transplantation.

Hepatopulmonary syndrome and portopulmonary hypertension

Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH) are serious pulmonary vascular complications of long-standing portal hypertension. Results from a recent study underscore the grave prognostic implications of HPS, finding that pretransplant HPS is a strong independent predictor of poor posttransplant survival (17% in patients with HPS vs 83% in those without) and higher risks of post-transplant biliary complications. While HPS is characterized by intrapulmonary vascular dilatations causing hypoxemia, PoPH involves pulmonary arterial hypertension. The 2 may coexist, complicating management. Liver transplantation is the definitive therapy for HPS and can be considered for PoPH, highlighting the critical need for routine screening (eg, pulse oximetry, echocardiography) in long-term follow-up.[44][45]

Malignancy

Malignant transformation, while rare in childhood, is a critical long-term concern. A 2025 systematic review of 57 reported cases identified hepatocellular carcinoma (HCC) as the predominant malignancy (73.7%), followed by cholangiocarcinoma (14%). The risk escalates with prolonged native liver survival into adolescence and adulthood, with an estimated HCC incidence of 1% to 2%. Surveillance is challenging; no standardized protocol exists, and tumor markers like alpha-fetoprotein (AFP) lack sensitivity, as many HCC cases were AFP-negative. This necessitates a low threshold for imaging (ultrasound and MRI) in native liver survivors, underscoring that portoenterostomy is a disease-modifying, not curative, intervention.[46]